Adalvo Acquires Branded Pain Product Onsolis
August 2, 2022
Adalvo has acquired full global rights to the branded opioid analgesic Onsolis from a U.S.-based specialty pharmaceutical owner, becoming the sole and exclusive owner of the product and assuming supply and market authorisation responsibilities worldwide. The product, indicated for management of breakthrough cancer pain in opioid-tolerant patients, is sold in several EU countries and Taiwan and Adalvo intends to integrate it into its expanding branded-product portfolio.
- Buyers
- Adalvo
- Targets
- Onsolis
- Industry
- Pharmaceuticals
- Location
- United States
- Transaction Type
- Divestiture
Explore More
Related Acquisitions
-
Soleo Health Acquires Realo Specialty Care Pharmacy and BluHaven Management
June 2, 2026
Healthcare Services
Soleo Health acquired Realo Specialty Care Pharmacy and BluHaven Management from parent company Realo Drugs. The deal expands Soleo Health’s presence in the Mid-Atlantic region, adding a specialty pharmacy in Morrisville, North Carolina and an ambulatory infusion center in Raleigh, North Carolina.
-
EQT X to Acquire Adalvo (B2B Generic Drug Dossiers)
July 18, 2025
Healthcare Services
EQT X (EQT) has agreed to acquire a majority stake in Adalvo, an asset-light B2B dossier developer that produces market-approval-ready generic drug dossiers for pharmaceutical companies. Existing shareholders, including Aztiq (holding company of Chairman Róbert Wessman), will reinvest part of their holdings and retain minority ownership. The deal is subject to customary approvals and is expected to close in H2 2025.
-
Oragenics Acquires Odyssey Health Neurological Drug Assets
January 2, 2024
Pharmaceuticals
Oragenics, Inc. completed the acquisition of Odyssey Health, Inc.'s neurological drug therapy assets, including ONP-002, ONP-001 rights, a proprietary intranasal delivery device and related formulations. Odyssey retained its remaining assets and operations; Michael Redmond (former Odyssey CEO) was named President of Oragenics to oversee integration and advancement of the neurology pipeline as Oragenics prepares for Phase 2 studies of ONP-002.
-
JanOne Inc. Agrees to Acquire Soin Therapeutics LLC
September 16, 2022
Pharmaceuticals
JanOne Inc. has executed a term sheet to acquire Soin Therapeutics LLC and its patent-pending low-dose naltrexone formulation (to be named JAN123) for the treatment of Complex Regional Pain Syndrome (CRPS). The deal is valued at $13 million up front with up to $17 million in additional contingent payments (total up to $30 million); JanOne expects to advance JAN123 into GMP manufacturing and file an IND in 2023.
-
Amneal Acquires Saol Therapeutics' Baclofen Franchise
January 5, 2022
Pharmaceuticals
Amneal Pharmaceuticals has agreed to acquire Saol Therapeutics' Baclofen franchise, including Lioresal and LYVISPAHTM, for approximately $83.5 million in cash plus certain low double-digit royalties. The deal expands Amneal's neurology and specialty portfolio, adds institutional commercial infrastructure ahead of its planned biosimilars launches, and is expected to be accretive to Amneal's 2022 adjusted EBITDA and EPS.
-
Altavant Sciences Acquires Onspira Therapeutics
January 8, 2020
Biotechnology
Altavant Sciences has acquired Onspira Therapeutics, adding OSP-101 — an inhaled interleukin-1 receptor antagonist with orphan drug designation for bronchiolitis obliterans syndrome (BOS) — to its rare respiratory disease pipeline. The deal closed with upfront and milestone payments to Onspira's shareholders and expands Altavant's capabilities in pulmonary transplant-related therapeutics.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.